Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab-Reference-Cited by-同舟云学术

Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab

Published:2017-10 Issue: Volume:183 Page:1-7
ISSN:1521-6616
Container-title:Clinical Immunology
language:en
Short-container-title:Clinical Immunology

Author:

Puissant-Lubrano Bénédicte,Puissochet Sylvain,Congy-Jolivet Nicolas,Chauveau Dominique,Decramer Stéphane,Garnier Arnaud,Huart Antoine,Kamar Nassim,Ribes David,Blancher Antoine

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference17 articles.

1. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom;Taylor;Br. J. Haematol.,2010

2. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab;Peffault de Latour;Blood,2015

3. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome;Cugno;J. Thromb. Haemost.,2014

4. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome;Volokhina;Clin. Immunol.,2015

5. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy;Noris;Blood,2014

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complement Blockade, a New Therapeutic Approach in Malignant Hypertension;Internal Medicine;2024-03-01

2. Complement Blockade, a New Therapeutic Approach in Malignant Hypertension;Internal Medicine;2023-12-01

3. The oxygen carrier M101 alleviates complement activation, which may be beneficial for donor organ preservation;Frontiers in Immunology;2022-09-12

4. Eculizumab treatment and discontinuation in pediatric patients with atypical hemolytic uremic syndrome: a multicentric retrospective study;Journal of Nephrology;2022-01-21

5. Deficiency of CFHR plasma proteins and autoantibody positive hemolytic uremic syndrome: treatment rationale, outcomes, and monitoring;Pediatric Nephrology;2020-06-12